AHA Scientific Sessions 2026 Abstract
Cardiomyopathy Masquerading as Cancer Therapy Related Cardiac Toxicity: A Multi-Hit Phenomenon?
Case reportCardiomyopathy
Papers on sacubitril + valsartan
41 papers14 new in 30 days
Monday, November 9
Saturday, November 7
Frontiers in Cardiovascular Medicine
Sacubitril/Valsartan versus Conventional Antihypertensive Therapy in Patients with Hypertension and Type 2 Diabetes
Accepted, not yet published: cohort study of 212 peopleSacubitril + valsartan
AHA Scientific Sessions 2026 Abstract
Three-Dimensional Dose-Response Surfaces of Cumulative Anthracycline or HER2-Targeted Therapy Exposure, Cardioprotective Agent Dose, and Physical Activity Volume on Incidence of Cancer Therapy-Related Cardiac Dysfunction: A Tensor Spline Meta-Analysis
Meta-analysis of studies in peopleAnthracyclines
AHA Scientific Sessions 2026 Abstract
Phenotypic and Transcriptomic Evaluation of Rodent Heart Failure with Preserved Ejection Fraction Models to Improve Predictive Validity in Drug Discovery
Experiments in miceHeart failure with preserved ejection fraction
Friday, November 6
Revista Brasileira de Psiquiatria
Drugs Associated with Dementia-Related Adverse Event Reports: A Real World Pharmacovigilance Study
Computational studyDementia
Wednesday, November 4
Thursday, October 29
Frontiers in Cardiovascular Medicine
Mechanisms and clinical outcomes of sacubitril-valsartan and SGLT2 inhibitors in heart failure patients: a retrospective cohort study
Cohort study of 150 peopleSGLT2 inhibitors
Monday, October 26
ESC Congress 2026 Abstract
Heart failure therapy optimization in myocardial infarction patients with systolic dysfunction during Phase 2 and 3 Cardiac Rehabilitation
Cohort study of 87 peopleCardiac rehabilitation
ESC Congress 2026 Abstract
Effect of sacubitril/valsartan and SGLT2 inhibitors on echocardiographic response and clinical outcomes after cardiac resynchronization therapy: insights from a real-world cohort
Cohort study of 206 peopleSGLT2 inhibitors
ESC Congress 2026 Abstract
Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials
Study of 18,823 peopleInterventions
ESC Congress 2026 Abstract
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Cohort study of 1,546 peopleDapagliflozin
ESC Congress 2026 Abstract
Treatment gradients across the left ventricular ejection fraction spectrum in ambulatory and acute heart failure: a multinational registry analysis
Cohort study of 6,729 peopleHeart failure
Monday, August 3
Annals of Internal Medicine
In symptomatic HF, sacubitril-valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo
Trial in peopleSacubitril + valsartan
Saturday, March 28
International Journal of Molecular Sciences
The Heart-Gut Axis in Heart Failure: The Role of Next-Generation Pharmacological Therapies
ReviewHeart failure
Wednesday, March 18
Journal of Clinical Hypertension
Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring
Non-randomized trial in 27 peopleSacubitril + valsartan
Monday, March 2
Monday, February 23
Friday, February 13
Journal of Clinical Medicine
The Impact of Introducing Sacubitril/Valsartan and SGLT2 Inhibitors in a Cohort of Patients with Reduced-Ejection-Fraction Heart Failure: A Real-Life Observational Study
Cohort study of 1,363 peopleSGLT2 inhibitors
Thursday, February 12
American Journal of Translational Research
Impact of sacubitril/valsartan on cardiac structure and function in post-acute myocardial infarction heart failure patients aged over 65: a single-center experience
Cohort study of 204 peopleSacubitril + valsartan
Tuesday, February 10
BMC Cardiovascular Disorders
Metabolic alterations associated with sacubitril/valsartan treatment: a systematic review and meta-analysis
Meta-analysis of studies in peopleSacubitril + valsartan
Monday, January 26
Iranian Journal of Basic Medical Sciences
Comparison of the therapeutic effects of sacubitril and valsartan combination versus metformin in experimentally induced polycystic ovary syndrome in rats
Experiments in ratsValsartan
Thursday, January 22
Current Pharmaceutical Research
Metabolic Syndrome: Pathophysiology, Clinical Implications, and Management Strategies
ReviewMetabolic syndrome
Wednesday, January 14
Hypertension Research
Impact of treatment strategies incorporating sacubitril/valsartan on achievement of guideline-recommended blood pressure targets and representative safety outcomes
Cohort study of 1,405 peopleSacubitril + valsartan
Thursday, January 1
Saturday, August 9
The American Journal of Cardiology
Differences in Characteristics and Clinical Outcomes According to Age in Patients Following High-Risk Myocardial Infarction: Insights from PARADISE-MI
Cohort study of 5,661 peopleMyocardial infarction
Saturday, July 6
European Journal of Pharmacology
Effects of sacubitril-valsartan on aging-related cardiac dysfunction
Experiments in ratsSacubitril + valsartan
Tuesday, April 9
Journal of General Internal Medicine
Frailty as an Effect Modifier in Randomized Controlled Trials: A Systematic Review
Systematic review of randomized trialsInterventions
Monday, March 11
Kardiologiia
Decompensation of Heart Failure in "Fragile" Patients: Clinical Features and Approaches to Therapy
Cohort study of 101 peopleHeart failure